In addition, our study reported the comprehensive mutation profile of a largest cohort of Chinese NSCLC patients with osimertinib resistance, which may contribute to the discovery of potential resistance mechanisms and the development of new EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.